Navigation Links
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Date:4/18/2008

CARLSBAD, Calif., April 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in Atlanta, Georgia. The data were presented in a poster entitled "Antisense Inhibition of Apolipoprotein B Ameliorated Diet-Induced Hypercholesterolemia and Reduced Atherosclerosis in LDL Receptor-Deficient Mice" by Adam E. Mullick, Ph.D. of Isis yesterday at ATVB.

Both studies were performed in a murine model in which the LDL receptor, which is responsible for the maintenance of normal serum cholesterol levels, has been genetically eliminated. These animals have very high cholesterol levels (1,000 - 2,000 mg/dL on a high fat diet) and develop severe atherosclerosis. In the first study, the impact of treatment with an antisense drug was evaluated in the context of two atherogenic high fat diets. Animals on these diets had elevated total cholesterol and LDL-cholesterol levels that increased during the two weeks of high fat diet prior to drug treatment. These cholesterol levels dramatically decreased during the 10 week treatment period. At a dose of 50 mg/kg twice weekly, the murine apoB-100 antisense drug reduced total cholesterol and LDL-cholesterol by 87% and 93%, respectively. These reductions in cholesterol directly correlated with reduction in liver and plasma apoB-100 levels. Aortic atherosclerotic lesions were reduced by 78% - 92% in the same animals.

The second study, which evaluated the effects of increasing doses of drug on lipid levels, confirms and extends the results of the previous study, and showed that the effects of the apoB-
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
6. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
7. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
8. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
11. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Eisai Limited is pleased to support the Canadian Epilepsy Alliance ... in Canada . The comic book, an ... and their parents about epilepsy, the most common neurological disorder ... Canadians. Eisai is guided by a corporate philosophy known as ... is central – there was a need within the epilepsy ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... N.Y. and HAMBURG, Germany , Aug. 21, 2014 ... is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a ... , to speed up management and storage of massive ... and Analytics architecture based on IBM software defined ... of data at peak performance and help scientists worldwide ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... Richard and Susan Smith Family,Foundation Announce Renewed Commitment ... 30 The American,Diabetes Association (ADA) has announced ... diabetes genes in mice, and potentially find new,drug ... type 2 diabetes. The,projects will be funded through ...
... a,pioneer in the development of novel products to ... announced that its Vice,President of Research, Johannes Fruehauf, ... World Congress meeting in Boston. His presentation, "Treatment ... 4:25 pm,on Friday, May 2, at the Hilton ...
Cached Medicine Technology:Continued Funding to Help Advance 'Exciting Moment' in Diabetes Research 2Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008 2Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008 3
(Date:8/22/2014)... 22, 2014 First Choice Emergency Room ... The facility is located at 8927 Highway 6, Missouri City, ... team is pleased to be a part of the Missouri ... emergency medical care to our neighbors here,” said Dr. Kenneth ... Plantation. , At yesterday’s ribbon cutting with the ...
(Date:8/22/2014)... Teen substance abuse has long been a ... numbers of young adults falling victim to a drug or ... a difference in the community, the new Troubled Teens Toledo ... seeking to overcome their chemical dependency. The helpline is designed ... rehab center to focus on achieving sobriety. , By contacting ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dr Murray Grossan ... this snoring cure. , In the October 2014 issue of ... Dr Grossan about his method of treating snoring, and in ... Dr Grossan: "Nearly half of all adults snore occasionally, and ... This is because air passages in the back of the ...
(Date:8/21/2014)... 22, 2014 Os-Monitor.com, an outstanding ... its new employee monitoring software collection ( http://www.os-monitor.com ... also announced that all these high end items ... With the tendency of improving productivity, the employers ... than before. Thus, employee and network monitoring software ...
(Date:8/21/2014)... Florida Hospital Zephyrhills is the first hospital ... in the Tampa Bay area to offer a ... Universal Platform for surgical endoscopy. The technology works ... provides the hospital a standardized solution for surgical ... care. Surgical endoscopy systems, through the collaborative use ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Missouri City, Texas 2Health News:New Helpline Provides Hope for Troubled Teens in Toledo 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3Health News:New Employee Monitoring Software Collection Unveiled By Os-Monitor.com 2Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 2Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 3
... According ... threat of a lawsuit causes many physicians to delay the adoption of medical innovations., , ... Atlanta, GA (Vocus) May 19, 2010 -- According ... threat of a lawsuit causes many physicians to delay the adoption of medical innovations. More ...
... as likely to develop problem , WEDNESDAY, May 19 ... possibly other similar medications, may prompt long-term hearing loss ... May 18 issue of the Archives of Otolaryngology ... University of Alabama at Birmingham discuss evidence supporting an ...
... ... brings writing tools that authors and writers have requested for years together, in ... York Times Bestselling Author Victor Ostrovsky as a solution for his ongoing needs ... more than 14 million Americans doing creative writing, likely a figure that has ...
... Malaga (UMA) have analysed the presence of voice disorders in ... statistic: 62.7% of the Early Childhood and Primary Education teaching ... basis. Professions such as teaching require a ... with vocal overload. "Our aim was to analyse the vocal ...
... (May 19, 2010) A Phase I clinical trial ... class of drugs that inhibit cyclin-dependent kinases, demonstrated the ... lymphocytic leukemia (CLL). Cyclin-dependent kinases are enzymatic proteins that ... and are thought to play key roles in the ...
... ... for the deadly childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research ... professor of The Ohio State University. , ... (PRWEB) May 19, 2010 -- Richmond, Virginia-based FightSMA, a nonprofit ...
Cached Medicine News:Health News:Lawsuit Fears Hinder Physician Adoption of Medical Innovations, Survey Finds 2Health News:Lawsuit Fears Hinder Physician Adoption of Medical Innovations, Survey Finds 3Health News:Viagra Linked to Hearing Loss 2Health News:TheBookPatch.com Launches: Writers Have Free Online Destination with Myriad Tools; Users Can Print One Book at a Time 2Health News:TheBookPatch.com Launches: Writers Have Free Online Destination with Myriad Tools; Users Can Print One Book at a Time 3Health News:More than 60 percent of teachers have voice problems 2Health News:Drug in new class of targeted therapies shows early promise against blood-related cancers 2Health News:Drug in new class of targeted therapies shows early promise against blood-related cancers 3Health News:FightSMA Awards $250,000 Grant to Gene Researcher at The Ohio State University 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: